Search results for "Plate"

showing 10 items of 1689 documents

Influence of Vascular Load on Plasma Endothelin-1, Cytokines and Catecholamine Levels in Essential Hypertensives

1998

In vitro studies demonstrated a relationship between ET-1 and basic Fibroblast Growth Factor (bFGF), and of bFGF with Platelet Derived Growth Factor (PDGF). The present study was carried out to investigate in vivo the behaviour after vascular stress of circulating ET-1, bFGF and PDGF, and catecholamines, and their relationship. In 12 healthy normotensives (NTs) and 15 essential hypertensives (Ehs) venous blood samples to determine circulating ET-1, bFGF and PDGF, and catecholamine (EPI and NE) levels were drawn before and at the third minute of a handgrip test. Blood pressures (BP) and heart rate were automatically recorded before starting, and at 1, 2, and 3 minutes during the test. The NT…

medicine.medical_specialtyPlatelet-derived growth factorBasic fibroblast growth factorMuscle Smooth Vascularchemistry.chemical_compoundCatecholaminesStress PhysiologicalInternal medicineBlood plasmaHeart rateInternal MedicinemedicineHumansPlatelet-Derived Growth FactorEndothelin-1Hand Strengthbiologybusiness.industryHypertrophyGeneral MedicineVenous bloodEndothelin 1EndocrinologychemistryVasoconstrictionHypertensioncardiovascular systembiology.proteinCatecholamineFibroblast Growth Factor 2Endothelium VascularCardiology and Cardiovascular MedicinebusinessPlatelet-derived growth factor receptorMuscle Contractionmedicine.drugBlood Pressure
researchProduct

Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified Curasan kit, with pr…

2003

Abstract The potential use of autologous thrombocytic growth factors to accelerate bone regeneration requires improved methods of isolating platelet-rich plasma (PRP). In addition to discontinuous cell separation, a second method by which PRP is produced at the point-of-care has now become available. In this study, growth factor levels in PRP from these two sources were compared. Whole blood was drawn from 115 healthy donors (73 males, 42 females) aged 21 - 62 years (mean 36, SD 10). The PRP was separated by the blood bank (BB) using the discontinuous cell separation method or at the 'point-of-care' by the so-called 'buffy coat' method (analogous to the Curasan PRP Kit). Growth factor conte…

medicine.medical_specialtyPlatelet-derived growth factorGrowth factormedicine.medical_treatmentBuffy coatBiologychemistry.chemical_compoundInsulin-like growth factorEndocrinologychemistryPlatelet-rich plasmaInternal medicinemedicinePlateletOral SurgeryBone regenerationWhole bloodClinical Oral Implants Research
researchProduct

Ethanol inhibits astroglial cell proliferation by disruption of phospholipase D-mediated signaling.

2002

The activation of phospholipase D (PLD) is a common response to mitogenic stimuli in various cell types. As PLD-mediated signaling is known to be disrupted in the presence of ethanol, we tested whether PLD is involved in the ethanol-induced inhibition of cell proliferation in rat cortical primary astrocytes. Readdition of fetal calf serum (FCS) to serum-deprived astroglial cultures caused a rapid, threefold increase of PLD activity and a strong mitogenic response; both effects were dependent on tyrosine kinases but not on protein kinase C. Ethanol (0.1-2%) suppressed the FCS-induced, PLD-mediated formation of phosphatidic acid (PA) as well as astroglial cell proliferation in a concentration…

medicine.medical_specialtyPlatelet-derived growth factorIndolestert-Butyl Alcoholmedicine.medical_treatmentButanolsBecaplerminPhosphatidic AcidsNerve Tissue ProteinsBiologyBiochemistryCulture Media Serum-FreeCellular and Molecular Neurosciencechemistry.chemical_compound1-ButanolInternal medicineLysophosphatidic acidmedicinePhospholipase DAnimalsPhosphorylationProtein kinase APlatelet-Derived Growth FactorEndothelin-1EthanolPhospholipase DCell growthGrowth factorPhosphatidic acidDNAProto-Oncogene Proteins c-sisProtein-Tyrosine KinasesGenisteinGrowth InhibitorsCell biologyRatsEndocrinologychemistryFetal Alcohol Spectrum DisordersAstrocyteslipids (amino acids peptides and proteins)Signal transductionVanadatesProtein Processing Post-TranslationalCell DivisionSignal TransductionJournal of neurochemistry
researchProduct

Strategies for managing Asherman's syndrome and endometrial atrophy: Since the classical experimental models to the new bioengineering approach

2021

Endometrial function is essential for embryo implantation and pregnancy, but managing endometrial thickness that is too thin to support pregnancy or an endometrium of compromised functionality due to intrauterine adhesions is an ongoing challenge in reproductive medicine. Here, we review current and emerging therapeutic and experimental options for endometrial regeneration with a focus on animal models used to study solutions for Asherman's syndrome and endometrial atrophy, which both involve a damaged endometrium. A review of existing literature was performed that confirmed the lack of consensus on endometrial therapeutic options, though promising new alternatives have emerged in recent ye…

medicine.medical_specialtyPregnancyPlatelet-Rich PlasmaRegeneration (biology)Reproductive medicineAsherman's syndromeGynatresiaCell BiologyBiologymedicine.diseaseBioinformaticsEndometriumENDOMETRIAL ATROPHYClinical trialDisease Models AnimalEndometriummedicine.anatomical_structureGeneticsmedicineAnimalsHumansFemaleStem cellStem Cell TransplantationDevelopmental BiologyMolecular Reproduction and Development
researchProduct

Pediatric non-red cell blood product transfusion practices: what's the evidence to guide transfusion of the ‘yellow’ blood products?

2020

Purpose of review Research studies pertaining to the management of pediatric non-red cell blood product transfusion is limited. Clinical practices vary within disciplines and regions. Anesthesiologists need evidence-based guidelines to make appropriate and safe decisions regarding transfusion of the 'yellow' blood products for pediatric patients. Recent findings This review outlines clinical indications for transfusion of fresh frozen plasma, cryoprecipitate, platelets, and fibrinogen concentrate in pediatrics. Recent studies of non-red blood cell transfusions in critical, but stable situations are highlighted. Recommendations to guide transfusion of the 'yellow' blood products in operative…

medicine.medical_specialtyRed Cellbusiness.industryMEDLINE030204 cardiovascular system & hematologyFibrinogenBlood cell03 medical and health sciences0302 clinical medicineAnesthesiology and Pain Medicinemedicine.anatomical_structureBlood productCryoprecipitatemedicinePlatelet030212 general & internal medicineFresh frozen plasmaIntensive care medicinebusinessmedicine.drugCurrent Opinion in Anaesthesiology
researchProduct

The Surgery of Neglected Distal Humerus Fractures in Children and Adults

2008

The restoration of function after a neglected distal humerus fracture presents a formidable challenge to the surgeon because of both the complexity of the regional anatomy and the proximity of numerous neurovascular structures. Inadequate or unstable fixation, a failure to reposition the articular fragments anatomically, prolonged post-operative immobilization, or the development of soft-tissue complications will result in substantial disability for the patient. Complications after injuries affecting a child’s elbow are common due to understimating the severity of the injury on the native X-rays where the growth plates and cartilage structures can not be seen.

medicine.medical_specialtyRegional anatomybusiness.industryElbowDistal humerusmusculoskeletal systemNeurovascular bundleDistal humerus fractureSurgeryFixation (surgical)medicine.anatomical_structuremedicineGrowth platesbusinessUlnar nerve
researchProduct

Antiplatelets in stroke prevention

2014

Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic st…

medicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINEPrimary preventionSecondary PreventionmedicineAnimalsHumanscardiovascular diseasesMyocardial infarctionIntensive care medicineStrokeCause of deathPharmacologySecondary preventionAspirinAspirinbusiness.industrymedicine.diseasePrimary PreventionStrokeCardiovascular DiseasesPhysical therapyPlatelet aggregation inhibitorantiplatelets Stroke preventionCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Antiplatelet treatment in ischemic stroke treatment.

2009

Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot. Immediate treatment with antiplatelet drugs such as aspirin may prevent new clots from forming and hence improve recovery after stroke. Several studies have evaluated the role of one antiplatelet agent, aspirin, in reducing stroke severity. The International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In thi…

medicine.medical_specialtySettore MED/09 - Medicina InternaTiclopidineBrain IschemiaInternal medicineDrug DiscoveryAntithromboticmedicineHumanscardiovascular diseasesPlatelet activationTiclopidineStrokeAspirinAspirinbusiness.industryGeneral Medicinemedicine.diseaseClopidogrelSurgeryClopidogrelStrokemedicine.anatomical_structureToxicityCardiologyantiplatelets strokeprevention treatmentbusinessPlatelet Aggregation Inhibitorsmedicine.drugArteryCurrent topics in medicinal chemistry
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

No Evidence for Classic Thrombotic Microangiopathy in COVID-19

2021

Background: Coronavirus disease-2019 (COVID-19) triggers systemic infection with involvement of the respiratory tract. There are some patients developing haemostatic abnormalities during their infection with a considerably increased risk of death. Materials and Methods: Patients (n = 85) with SARS-CoV-2 infection attending the University Medical Center, Mainz, from 3 March to 15 May 2020 were retrospectively included in this study. Data regarding demography, clinical features, treatment and laboratory parameters were analyzed. Twenty patients were excluded for assessment of disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) due to lack of laboratory data. Resu…

medicine.medical_specialtyThrombotic microangiopathymicroangiopathylcsh:Medicine030204 cardiovascular system & hematologyFibrinogenGastroenterologyArticleProcalcitonin03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicinePlateletdisseminated intravascular coagulationDisseminated intravascular coagulationbusiness.industrylcsh:RMicroangiopathyCOVID-19General Medicinemedicine.diseaseADAMTS13ADAMTS13Blood pressurecoronavirus disease030220 oncology & carcinogenesisbusinessmedicine.drugJournal of Clinical Medicine
researchProduct